Abbott Biotherapeutics Corp.
Records under this name other than the patents Abbott Biotherapeutics Corp. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Back to Abbott Biotherapeutics Corp.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,283,170 | Immunoglobulin display vectors Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,709,610 | Therapeutic Use of ANTI-CS1 Antibodies Formerly held In force · Low confidence | In force | Low confidence | |
| US 8,658,175 | Anti-EGFR antibodies and their uses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,937,159 | Anti-HER2 antibodies and their uses Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,399,469 | ANTI-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer Formerly held Term ended Term ended Mar 29, 2026 · High confidence | Term ended | Term ended Mar 29, 2026 | High confidence |
| US 8,633,139 | Methods of Screening Complex Protein Libraries to Identify Altered Properties Formerly held Lapsed on the fee record Ended Jan 21, 2026 · Medium confidence | Lapsed on the fee record | Ended Jan 21, 2026 | Medium confidence |
| US 10,442,859 | Therapeutic Use of ANTI-CS1 Antibodies Formerly held Term ended Term ended Aug 19, 2025 · Medium confidence | Term ended | Term ended Aug 19, 2025 | Medium confidence |
| US 7,276,372 | Antibodies Against GPR64 and Uses Thereof Term ended Term ended Jun 22, 2025 · High confidence | Term ended | Term ended Jun 22, 2025 | High confidence |
| US 7,276,589 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis Formerly held Term ended Term ended Jan 11, 2025 · High confidence | Term ended | Term ended Jan 11, 2025 | High confidence |
| US 7,879,987 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis Formerly held Term ended Term ended Dec 20, 2024 · High confidence | Term ended | Term ended Dec 20, 2024 | High confidence |